Sugi Predict

Sugi Predict / Targets / PSMA3

PSMA3

Proteasome subunit alpha type-3 · P25788 · PSMA3 on Sugi Atlas →

23,564 patent compounds predicted against PSMA3, 16,159 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL609327 SCHEMBL609327 0.55 12/20
SCHEMBL607553 SCHEMBL607553 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL609081 SCHEMBL609081 0.52 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1327404 SCHEMBL1327404 0.50 12/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL609733 SCHEMBL609733 0.60 11/20
SCHEMBL609324 SCHEMBL609324 0.60 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20
SCHEMBL609290 SCHEMBL609290 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20

Clinical trials — most relevant to PSMA3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy PHASE4RECRUITING
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers PHASE2/PHASE3RECRUITING
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function PHASE2ACTIVE_NOT_RECRUITING
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer PHASE2COMPLETED
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours: PHASE2ACTIVE_NOT_RECRUITING
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning PHASE1/PHASE2SUSPENDED
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC PHASE1/PHASE2WITHDRAWN
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer PHASE1/PHASE2RECRUITING
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer PHASE1COMPLETED
The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma PHASE1RECRUITING
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT EARLY_PHASE1RECRUITING
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 nanCOMPLETED
A Prospective, Single-centre，Single-blinded Study of PROUD for Prostate Carcinoma Diagnosis nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Identification of Molecular Marker of Coagulase-negative Staphylococci for the Diagnosis of Prosthetic Joint Infections nanUNKNOWN
Prostate Cancer Antigen 3 (PCA-3) Gene Project nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients nanNOT_YET_RECRUITING
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
177Lu-PSMA-617 Managed Access Program for mCRPC Patients nanNO_LONGER_AVAILABLE

Related proteins — ESM-2 sequence neighbours (a PSMA3 binder may also engage these)

ProteinNameSimilarity
P18422 — 1.000 P18422 →
Q58DU5 — 1.000 Q58DU5 →
O70435 — 1.000 O70435 →
Q9V5C6 — 1.000 Q9V5C6 →
Q27563 — 1.000 Q27563 →
P22769 — 0.999 P22769 →
O16811 — 0.999 O16811 →
Q27488 — 0.999 Q27488 →
P90513 — 0.999 P90513 →
Q9CWH6 — 0.999 Q9CWH6 →
Q54XM7 — 0.998 Q54XM7 →
P21243 — 0.998 P21243 →
Q9LSU0 — 0.998 Q9LSU0 →
P40303 — 0.998 P40303 →
O24362 — 0.998 O24362 →
Q0J006 — 0.998 Q0J006 →
Q3T0X5 — 0.997 Q3T0X5 →
A2YXU2 — 0.997 A2YXU2 →
O13268 — 0.997 O13268 →
O23715 — 0.996 O23715 →
Q9Z2U0 — 0.996 Q9Z2U0 →
PSMA8 Proteasome subunit alpha-type 8 (Proteasome a 0.996 landscape →
Q5RDH8 — 0.996 Q5RDH8 →
Q10329 — 0.996 Q10329 →
Q24178 — 0.996 Q24178 →
Q9UXC6 — 0.996 Q9UXC6 →
Q3ZBG0 — 0.995 Q3ZBG0 →
Q9PVQ1 — 0.995 Q9PVQ1 →
C3MVG1 — 0.995 C3MVG1 →
P48004 — 0.995 P48004 →